USD 23.33
| ticker | 1 day return % | 1 week return % | 1 month return % | 3 months return % | 6 months return % | 1 year return % | 3 years return % | 5 years return % | 10 years return % | maximum return % |
|---|---|---|---|---|---|---|---|---|---|---|
| NAMS | -1.6 | -0.7 | -8.5 | 23.3 | 22.8 | 10.6 | 139.3 | 119.8 | 119.8 | 119.8 |
| S&P 500 | 0.7 | 1.6 | 2.7 | 4.1 | 9.5 | 25.6 | 38.1 | 83.4 | 195.3 | 34395.7 |
Our interactive price chart includes various drawing tools to help you analyze the product more effectively. Below is a quick guide on how to use these tools: Full Guideline
Feel free to experiment with these tools to enhance your technical analysis. Remember, any drawings you make are temporary and will be lost upon refreshing the page unless saved as an image using the 'Camera' icon.
Get instant AI-powered professional insights on prices:
💡Generate AI Technical Analysis ReportA Multi-Interval Candlestick Chart displays the price movements of an asset over different time intervals. Each candlestick represents the open, high, low, and close prices for a specific interval. The chart can be used to identify trends and patterns in price movements.
| Attribute | Value |
|---|---|
| symbol | NAMS |
| name | NewAmsterdam Pharma Company N.V. |
| price | 23.33 |
| changes percentage | -1.5612 |
| change | -0.37 |
| day low | 23.04 |
| day high | 23.59 |
| year high | 27.29 |
| year low | 15.19 |
| market cap | 2492413890 |
| price avg 50 | 23.5658 |
| price avg 200 | 19.814425 |
| exchange | NASDAQ |
| volume | 560718 |
| avg volume | 851278 |
| open | 23.5 |
| previous close | 23.7 |
| eps | -2.21 |
| pe | -10.56 |
| earnings announcement | 2025-02-26T05:00:00.000+0000 |
| shares outstanding | 106833000 |
| timestamp | 2025-01-22 19:12:28 |
We derive the score of a company's financial statements by evaluating the weighted average sentiment across key within the statements. The cumulative score, normalized to a sum of 1, serves as a metric for assessing the company's performance during the specified period. A higher score indicates stronger performance. However, it's crucial to note that while this score provides valuable insights, it is just one of many factors to consider when making informed investment decisions. A holistic evaluation, considering various aspects of the company's financial health and market conditions, is essential for a well-rounded investment strategy.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001936258 | |||
| revenue | 12762722 | 95905926 | -86.69 |
| gross profit | 12762722 | 95905926 | -86.69 |
| gross profit ratio | 1 | 1 | 0.00 |
| research and development expenses | 159424000 | 81010221 | 96.79 |
| operating expenses | 197057000 | 116775789 | 68.75 |
| interest income | 10220141 | 268029 | 3713.07 |
| interest expense | 6799141 | 0 | NaN |
| ebitda | -176861000 | -3313477 | -5237.63 |
| ebitdaratio | -13.86 | -0.03 | -40009.78 |
| operating income | -165731508 | -3321882 | -4889.08 |
| operating income ratio | -12.99 | -0.03 | -37390.65 |
| net income | -176937000 | -21137892 | -737.06 |
| net income ratio | -13.86 | -0.22 | -6190.12 |
| eps | -2.15 | -1.11 | -93.69 |
Revenue Growth: revenue decreased to 13 million in 2023 from 96 million in 2022 representing a change of -86.69%. This indicates a sales shrinking, which is a negative sign for the company.
Gross Profit: Gross Profit decreased to 13 million in 2023 from 96 million in 2022 representing a change of -86.69%. This indicates a sales profitability decline, which is a negative sign for the company.
Research and Development (R&D) Expenses: R&D Expenses decreased to 159 million in 2023 from 81 million in 2022 representing a change of 96.79%. This shows that the company decreased investment in innovation and product development, which is not a good sign for long-term growth.
Operating Expenses: Operating Expenses increased to 197 million in 2023 from 117 million in 2022 representing a change of 68.75%. The increase in operating expenses can be attributed to various factors such as marketing, administrative costs, and investments in infrastructure. It's important to monitor if these expenses are growing at a sustainable rate compared to revenue.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) decreased to -177 million in 2023 from -3 million in 2022 representing a change of -5237.63%. The decrease in EBITDA indicates declined operational efficiency and profitability.
Operating Income: Operating income decreased to -166 million in 2023 from -3 million in 2022 representing a change of -4889.08%. The decrease in operating income indicates worse operational performance and decreased profitability.
Net Income: Net income decreased to -177 million in 2023 from -21 million in 2022 representing a change of -737.06%. The decrease in net income shows worsen profitability and indicates that the company is generating less profit for each dollar of revenue.
Earnings per Share (EPS): EPS increased to -2.15 in 2023 from -2.15 in 2022 representing a change of -93.69%. This indicates that the company's earnings are decreasing and it is becoming less profitable on a per-share basis.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001936258 | |||
| revenue | 29111000 | 2127446 | 1268.35 |
| gross profit | 29111000 | 2109708 | 1279.86 |
| gross profit ratio | 1 | 0.99 | 0.84 |
| research and development expenses | 35702000 | 35826796 | -0.35 |
| operating expenses | 54114000 | 43086626 | 25.59 |
| interest income | 4443000 | 4546145 | -2.27 |
| interest expense | 1135000 | 853145 | 33.04 |
| ebitda | -23840000 | -49061026 | 51.41 |
| ebitdaratio | -0.82 | -23.06 | 96.45 |
| operating income | -24364000 | -49078762 | 50.36 |
| operating income ratio | -0.84 | -23.07 | 96.37 |
| net income | -16647000 | -36413034 | 54.28 |
| net income ratio | -0.57 | -17.12 | 96.66 |
| eps | -0.18 | -0.38 | 52.63 |
Revenue Growth: revenue increased to 29 million in 2024Q3 from 2 million in 2024Q2 representing a change of 1268.35%. This indicates a sales growth, which is a positive sign for the company.
Gross Profit: Gross Profit increased to 29 million in 2024Q3 from 2 million in 2024Q2 representing a change of 1279.86%. This indicates a sales profitability growth, which is a positive sign for the company.
Earnings per Share (EPS): EPS increased to -0.18 in 2024Q3 from -0.18 in 2024Q2 representing a change of 52.63%. This indicates that the company's earnings are increasing and it is becoming more profitable on a per-share basis.
Research and Development (R&D) Expenses: R&D Expenses decreased to 36 million in 2024Q3 from 36 million in 2024Q2 representing a change of -0.35%. This shows that the company decreased investment in innovation and product development, which is not a good sign for long-term growth.
Operating Expenses: Operating Expenses increased to 54 million in 2024Q3 from 43 million in 2024Q2 representing a change of 25.59%. The increase in operating expenses can be attributed to various factors such as marketing, administrative costs, and investments in infrastructure. It's important to monitor if these expenses are growing at a sustainable rate compared to revenue.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) decreased to -24 million in 2024Q3 from -49 million in 2024Q2 representing a change of 51.41%. The decrease in EBITDA indicates declined operational efficiency and profitability.
Operating Income: Operating income decreased to -24 million in 2024Q3 from -49 million in 2024Q2 representing a change of 50.36%. The decrease in operating income indicates worse operational performance and decreased profitability.
Net Income: Net income decreased to -17 million in 2024Q3 from -36 million in 2024Q2 representing a change of 54.28%. The decrease in net income shows worsen profitability and indicates that the company is generating less profit for each dollar of revenue.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001936258 | |||
| total assets | 347097000 | 531583000 | -34.71 |
| total liabilities | 58704000 | 47062000 | 24.74 |
| total equity | 288393000 | 484521000 | -40.48 |
| cash and cash equivalents | 340450000 | 438522000 | -22.36 |
| short term investments | 0 | 0 | NaN |
| long term investments | 0 | 0 | NaN |
| total current assets | 346791000 | 448133000 | -22.61 |
| total non current assets | 306000 | 83450000 | -99.63 |
| total current liabilities | 49897000 | 35461000 | 40.71 |
| total non current liabilities | 8807000 | 11601000 | -24.08 |
| common stock | 10173000 | 599191000 | -98.30 |
| retained earnings | -316973000 | -119361000 | -165.56 |
| total debt | 60000 | 118000 | -49.15 |
Total Assets: Total Assets decreased to 347 million in 2023 from 532 million in 2022 representing a change of -34.71%. Suggesting a decrease in asset holdings.
Total Liabilities: Total Liabilities increased to 59 million in 2023 from 47 million in 2022 representing a change of 24.74%. This indicates an increase in overall liabilities.
Total Equity: Total Equity decreased to 288 million in 2023 from 485 million in 2022 representing a change of -40.48%. This indicates a decrease in shareholders' equity.
Cash And Cash Equivalents: Cash And Cash Equivalents decreased to 340 million in 2023 from 439 million in 2022 representing a change of -22.36%. This indicates a decrease in available liquid assets.
Total Current Assets: Total Current Assets decreased to 347 million in 2023 from 448 million in 2022 representing a change of -22.61%. This indicates a worsen liquidity position.
Total Current Liabilities: Total Current Liabilities increased to 50 million in 2023 from 35 million in 2022 representing a change of 40.71%. This indicates a higher short-term debt burden.
Common Stock: Common Stock decreased to 10 in 2023 from 599 in 2022 representing a change of -98.3%. This indicates a decrease in ownership interest.
Retained Earnings: Retained Earnings decreased to -317 million in 2023 from -119 million in 2022 representing a change of -165.56%. This indicates an accumulated losses.
Total Debt: Total Debt decreased to 0 million in 2023 from 0 million in 2022 representing a change of -49.15%. This indicates a reduction in overall debt burden.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001936258 | |||
| total assets | 439191000 | 416225742 | 5.52 |
| total liabilities | 60329000 | 55210081 | 9.27 |
| total equity | 378862000 | 361015660 | 4.94 |
| cash and cash equivalents | 422729000 | 401333714 | 5.33 |
| short term investments | 0 | 0 | NaN |
| long term investments | 0 | 0 | NaN |
| total current assets | 437874000 | 414978993 | 5.52 |
| total non current assets | 1317000 | 1246748 | 5.63 |
| total current liabilities | 41255000 | 42217062 | -2.28 |
| total non current liabilities | 19074000 | 12993019 | 46.80 |
| common stock | 11435000 | 10390501 | 10.05 |
| retained earnings | -466394000 | -419074254 | -11.29 |
| total debt | 506000 | 523671 | -3.37 |
Total Assets: Total Assets increased to 439 million in 2024Q3 from 416 million in 2024Q2 representing a change of 5.52%. Suggesting a growth in asset holdings.
Total Equity: Total Equity increased to 379 million in 2024Q3 from 361 million in 2024Q2 representing a change of 4.94%. This indicates an increase in shareholders' equity.
Cash And Cash Equivalents: Cash And Cash Equivalents increased to 423 million in 2024Q3 from 401 million in 2024Q2 representing a change of 5.33%. This indicates an increase in available liquid assets.
Total Current Assets: Total Current Assets increased to 438 million in 2024Q3 from 415 million in 2024Q2 representing a change of 5.52%. This indicates a better liquidity position.
Total Current Liabilities: Total Current Liabilities decreased to 41 million in 2024Q3 from 42 million in 2024Q2 representing a change of -2.28%. This indicates a lower short-term debt burden.
Common Stock: Common Stock increased to 11 in 2024Q3 from 10 in 2024Q2 representing a change of 10.05%. This indicates an increase in ownership interest.
Total Debt: Total Debt decreased to 1 million in 2024Q3 from 1 million in 2024Q2 representing a change of -3.37%. This indicates a reduction in overall debt burden.
Total Liabilities: Total Liabilities increased to 60 million in 2024Q3 from 55 million in 2024Q2 representing a change of 9.27%. This indicates an increase in overall liabilities.
Retained Earnings: Retained Earnings decreased to -466 million in 2024Q3 from -419 million in 2024Q2 representing a change of -11.29%. This indicates an accumulated losses.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001936258 | |||
| net change in cash | -127278000 | 385430000 | -133.02 |
| operating cash flow | -141218000 | 7972000 | -1871.42 |
| free cash flow | -141242000 | 7959000 | -1874.62 |
| capital expenditure | -24000 | -13000 | -84.62 |
| depreciation and amortization | 49000 | 72000 | -31.94 |
| deferred income tax | 0 | 0 | NaN |
| stock based compensation | 24572000 | 4117000 | 496.84 |
| accounts payables | 5070000 | -2025844 | 350.27 |
| inventory | 0 | 5929252 | -100.00 |
| acquisitions net | 0 | 0 | NaN |
| investments in property plant and equipment | -24000 | -13000 | -84.62 |
| net cash used for investing activites | -24000 | 715000 | -103.36 |
| debt repayment | 0 | 747000 | -100.00 |
| common stock issued | 7337163 | 396952000 | -98.15 |
| common stock repurchased | 0 | 0 | NaN |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | 8912000 | 375177000 | -97.62 |
| cash at end of period | 340450000 | 438522000 | -22.36 |
| accounts receivables | 0 | -3903408 | 100.00 |
| cash at beginning of period | 467728000 | 53092000 | 780.98 |
Net Change in Cash: Net Change in Cash decreased to -127 million in 2023 from 385 million in 2022 representing a change of -133.02%. Indicating a declined ability to generate cash from the company's operations or its cash flow position.
Operating Cash Flow: Operating Cash Flow decreased to -141 million in 2023 from 8 million in 2022 representing a change of -1871.42%. This indicates that the company generated less cash from its core business operations.
Free Cash Flow: Free Cash Flow decreased to -141 million in 2023 from 8 million in 2022 representing a change of -1874.62%. This indicates a decrease in cash generated after accounting for capital expenditures.
Stock-Based Compensation: Stock-Based Compensation increased to 25 million in 2023 from 4 million in 2022 representing a change of 496.84%. This indicates increased expenses, which is generally considered a negative sign from a financial perspective.
Accounts Payables: The absolute value of Accounts Payables increased to 5 million in 2023 from 2 million in 2022 representing a change of 350.27%. This indicates that the company has increased its outstanding obligations to its suppliers.
Accounts Receivables: Accounts Receivables increased to 0 in 2023 from -4 million in 2022 representing a change of 100.0%. This suggests that the company is less capable of collecting payments from its customers.
Capital Expenditure: Capital Expenditure decreased to 0 million in 2023 from 0 million in 2022 representing a change of -84.62%. This indicates a possible improved efficiency or a shift in the company's strategic priorities.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001936258 | |||
| operating cash flow | -12502000 | -50297632 | 75.14 |
| free cash flow | -12577000 | -50492378.2 | 75.09 |
| capital expenditure | -75000 | -194746.2 | 61.49 |
| depreciation and amortization | 28000 | 17704 | 58.16 |
| deferred income tax | 0 | 0 | NaN |
| stock based compensation | 7996000 | 7724622 | 3.51 |
| accounts receivables | 0 | -8619015 | 100.00 |
| accounts payables | 1905000 | -3116871 | 161.12 |
| inventory | 0 | 0 | NaN |
| acquisitions net | 0 | 0 | NaN |
| investments in property plant and equipment | -75000 | -194746.2 | 61.49 |
| net cash used for investing activites | -75000 | -194746.2 | 61.49 |
| debt repayment | 0 | 0 | NaN |
| common stock issued | 58000 | 4348719 | -98.67 |
| common stock repurchased | 0 | 0 | NaN |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | 58000 | 4340324 | -98.66 |
| net change in cash | -7979000 | -46999060 | 83.02 |
| cash at end of period | 422729000 | 401333714 | 5.33 |
| cash at beginning of period | 430708000 | 448332774 | -3.93 |
EPS represents the portion of a company's profit allocated to each outstanding share of common stock. A higher EPS is generally favorable, indicating stronger profitability on a per-share basis.
Positive EPS: A positive EPS signifies that a company is profitable, it is generally viewed positively, supporting stock value and investor confidence.
Negative EPS: Indicates that a company is operating at a loss, which could lead to negative sentiment, potential stock depreciation, and concerns about the company's financial health.
The Next Earning Date represents when the company plans to release its next set of financial results.
An upward trend in EPS suggests consistent growth in earnings, often leading to increased investor confidence. A downward trend may indicate a decline in earnings, potentially decreasing investor confidence and stock value. Fluctuating EPS suggests unpredictable financial performance, warranting cautious investor analysis.
Earnings surprise occurs when a company's actual earnings differ from analysts' expectations. A positive earnings surprise typically reflects better-than-expected performance, potentially leading to stock appreciation. Conversely, a negative earnings surprise can result in stock depreciation. An earnings surprise of zero means the earnings met expectations, which typically has a neutral impact on stock price.
Discover detailed analyst recommendations for stocks, including categories such as Buy, Hold, Sell, Strong Buy, and Strong Sell. These insights are based on thorough analysis of financial and market factors. The consensus is calculated by assigning a numerical score to each recommendation. These scores are then weighted and averaged over a specified period to provide a comprehensive view of the stock's outlook, with the final score determining the overall consensus.
| 2023-12-31 | 2022-12-31 | Y/Y change % | |
|---|---|---|---|
| FY | |||
| calendar year | 2023 | 2022 | NaN |
| revenue per share | 0.16 | 5.06 | -96.93 |
| net income per share | -2.15 | -1.11 | -93.23 |
| operating cash flow per share | -1.72 | 0.42 | -508.92 |
| free cash flow per share | -1.72 | 0.42 | -509.66 |
| cash per share | 4.14 | 23.12 | -82.08 |
| book value per share | 3.51 | 25.55 | -86.26 |
| tangible book value per share | 3.51 | 21.16 | -83.42 |
| shareholders equity per share | 3.51 | 25.55 | -86.26 |
| interest debt per share | 0.08 | 0.01 | 1241.86 |
| market cap | 917727200 | 206731961.5 | 343.92 |
| enterprise value | 577337200 | -231672038.5 | 349.20 |
| pe ratio | -5.19 | -9.78 | 46.97 |
| price to sales ratio | 71.91 | 2.16 | 3235.86 |
| pocfratio | -6.5 | 25.93 | -125.06 |
| pfcf ratio | -6.5 | 25.97 | -125.02 |
| pb ratio | 3.18 | 0.43 | 645.82 |
| ptb ratio | 3.18 | 0.43 | 645.82 |
| ev to sales | 45.24 | -2.42 | 1972.66 |
| enterprise value over ebitda | -3.26 | 69.92 | -104.67 |
| ev to operating cash flow | -4.09 | -29.06 | 85.93 |
| ev to free cash flow | -4.09 | -29.11 | 85.96 |
| earnings yield | -0.19 | -0.1 | -88.56 |
| free cash flow yield | -0.15 | 0.04 | -499.76 |
| debt to equity | 0.0 | 0.0 | -14.57 |
| debt to assets | 0.0 | 0.0 | -22.13 |
| net debt to ebitda | 1.92 | 132.31 | -98.55 |
| current ratio | 6.95 | 12.64 | -45.00 |
| interest coverage | -24.38 | 0 | NaN |
| income quality | 0.8 | -0.1 | 881.43 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 2.01 | 0 | NaN |
| research and ddevelopement to revenue | 12.49 | 0.84 | 1378.82 |
| intangibles to total assets | 0.0 | 0.16 | -99.69 |
| capex to operating cash flow | -0.0 | 0.0 | -110.42 |
| capex to revenue | 0.0 | 0.0 | 1287.30 |
| capex to depreciation | 0.49 | 0.18 | 171.27 |
| stock based compensation to revenue | 1.93 | 0.04 | 4384.99 |
| graham number | 13.04 | 25.31 | -48.47 |
| roic | -0.56 | -0.01 | -8229.21 |
| return on tangible assets | -0.51 | -0.05 | -981.95 |
| graham net net | 3.45 | 20.72 | -83.37 |
| working capital | 296894000 | 412672000 | -28.06 |
| tangible asset value | 288223000 | 401361000 | -28.19 |
| net current asset value | 288087000 | 401071000 | -28.17 |
| invested capital | 297165000 | 495976000 | -40.08 |
| average receivables | 1975500 | 3463613 | -42.96 |
| average payables | 14388000 | 9447140 | 52.30 |
| average inventory | 10750 | 10382.5 | 3.54 |
| days sales outstanding | 53.79 | 7.88 | 582.84 |
| days payables outstanding | 0 | 0 | NaN |
| days of inventory on hand | 0 | 0 | NaN |
| receivables turnover | 6.79 | 46.33 | -85.36 |
| payables turnover | 0 | 0 | NaN |
| inventory turnover | 0 | 0 | NaN |
| roe | -0.61 | -0.04 | -1306.32 |
| capex per share | 0.0 | 0.0 | -57.38 |
ROE: Return on Equity (ROE) decreased to -0.61 on 2023-12-31 from -0.04 on 2022-12-31, representing a change of -1306.32%. Suggesting that the company has not been generating high returns for its shareholders.
Current Ratio: Current Ratio decreased to 6.95 on 2023-12-31 from 12.64 on 2022-12-31, representing a change of -45.00%. The current ratio has been declining, suggesting a decrease in the company's short-term liquidity. Since it's above 3, indicating poor management of working capital.
PE Ratio: Price-to-Earnings (P/E) Ratio increased to -5.19 on 2023-12-31 from -9.78 on 2022-12-31, representing a change of 46.97%. Indicating an increase in the relative valuation of the company's stock.
Debt-to-Equity Ratio: Debt-to-Equity Ratio decreased to 0.00 on 2023-12-31 from 0.00 on 2022-12-31, representing a change of -14.57%. The debt-to-equity ratio has been decreasing, indicating that the company has been relying less on debt financing. A ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
| 2024-09-30 Q3 | 2024-06-30 Q2 | Q/Q change % | |
|---|---|---|---|
| NAMS | |||
| calendar year | 2024 | 2024 | NaN |
| revenue per share | 0.31 | 0.02 | 1267.74 |
| net income per share | -0.18 | -0.38 | 54.30 |
| operating cash flow per share | -0.13 | -0.53 | 75.16 |
| free cash flow per share | -0.13 | -0.53 | 75.10 |
| cash per share | 4.46 | 4.24 | 5.28 |
| book value per share | 4.0 | 3.81 | 4.90 |
| tangible book value per share | 3.99 | 3.81 | 4.88 |
| shareholders equity per share | 4.0 | 3.81 | 4.90 |
| interest debt per share | 0.02 | 0.01 | 19.13 |
| market cap | 1572918724.0 | 1949164810.32 | -19.30 |
| enterprise value | 1150695724.0 | 1548354767.32 | -25.68 |
| pe ratio | -23.62 | -13.38 | -76.51 |
| price to sales ratio | 54.03 | 916.2 | -94.10 |
| pocfratio | -125.81 | -38.75 | -224.66 |
| pfcf ratio | -125.06 | -38.6 | -223.97 |
| pb ratio | 4.15 | 5.4 | -23.10 |
| ptb ratio | 4.15 | 5.4 | -23.10 |
| ev to sales | 39.53 | 727.8 | -94.57 |
| enterprise value over ebitda | -48.27 | -31.56 | -52.94 |
| ev to operating cash flow | -92.04 | -30.78 | -198.99 |
| ev to free cash flow | -91.49 | -30.67 | -198.36 |
| earnings yield | -0.01 | -0.02 | 43.35 |
| free cash flow yield | -0.01 | -0.03 | 69.13 |
| debt to equity | 0.0 | 0.0 | -7.93 |
| debt to assets | 0.0 | 0.0 | -8.43 |
| net debt to ebitda | 17.71 | 8.17 | 116.79 |
| current ratio | 10.61 | 9.83 | 7.98 |
| interest coverage | -21.47 | -57.53 | 62.69 |
| income quality | 0.75 | 1.38 | -45.73 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 0.47 | 5.68 | -91.70 |
| research and ddevelopement to revenue | 1.23 | 16.84 | -92.72 |
| intangibles to total assets | 0.0 | 0.0 | 11.28 |
| capex to operating cash flow | -0.01 | -0.0 | -54.94 |
| capex to revenue | 0.0 | 0.09 | -97.19 |
| capex to depreciation | 2.68 | 11.0 | -75.65 |
| stock based compensation to revenue | 0.27 | 3.63 | -92.44 |
| graham number | 3.98 | 5.74 | -30.77 |
| roic | -0.06 | -0.13 | 53.34 |
| return on tangible assets | -0.04 | -0.09 | 56.67 |
| graham net net | 3.87 | 3.63 | 6.55 |
| working capital | 396619000 | 372761931 | 6.40 |
| tangible asset value | 378269000 | 360510626 | 4.93 |
| net current asset value | 377545000 | 359768912 | 4.94 |
| invested capital | 397936000 | 374001224 | 6.40 |
| average receivables | 2573000 | 2066500 | 24.51 |
| average payables | 6157000 | 6905500 | -10.84 |
| average inventory | -2518655.4 | -2518654.93 | -0.00 |
| days sales outstanding | 15.91 | 0 | NaN |
| days payables outstanding | 0 | 26764.57 | -100.00 |
| days of inventory on hand | 0 | -25558.57 | 100.00 |
| receivables turnover | 5.66 | 0 | NaN |
| payables turnover | 0 | 0.0 | -100.00 |
| inventory turnover | 0 | -0.0 | 100.00 |
| roe | -0.04 | -0.1 | 56.44 |
| capex per share | 0.0 | 0.0 | -61.51 |
ROE: Return on Equity (ROE) increased to -0.04 on 2024-09-30 Q3 from -0.10 on 2024-06-30 Q2, representing a change of 56.44%. However, ROE is <= 5%, suggesting that the company has not been generating high returns for its shareholders.
PE Ratio: Price-to-Earnings (P/E) Ratio decreased to -23.62 on 2024-09-30 Q3 from -13.38 on 2024-06-30 Q2, representing a change of -76.51%. Indicating a decrease in the relative valuation of the company's stock.
Current Ratio: Current Ratio increased to 10.61 on 2024-09-30 Q3 from 9.83 on 2024-06-30 Q2, representing a change of 7.98%. The current ratio has been increasing, suggesting an increase in the company's short-term liquidity. Since it's above 3, indicating poor management of working capital.
Debt-to-Equity Ratio: Debt-to-Equity Ratio decreased to 0.00 on 2024-09-30 Q3 from 0.00 on 2024-06-30 Q2, representing a change of -7.93%. The debt-to-equity ratio has been decreasing, indicating that the company has been relying less on debt financing. A ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
Negative Sentiment: Discounted Cash Flow value is 4.56 which is lower than current price 23.33, indicates the company may be overvalued.
| Market Capitalization | Enterprise Value | |
|---|---|---|
| Definition | The total market value of a company's outstanding shares | The total market value of a company, including its debt and other liabilities |
| Calculation | Current share price * Total number of outstanding shares | Market capitalization + Total debt - Cash and cash equivalents |
| Focus | Equity component of a company's value | Total economic value of a company |
| Usefulness | Assesses a company's size and growth potential based on investor sentiment | Provides a more comprehensive valuation that considers both equity and debt |
Analyzing dividends is a crucial aspect of investment evaluation, offering valuable insights into a company's financial health and its commitment to shareholder returns. Dividends represent a portion of a company's profits distributed to its shareholders, providing a steady income stream. We help you analyze dividends based on the indicators mentioned below:
• Investors often assess the average dividend amount, observing trends over time to gauge the company's stability and growth potential. A positive trend in average dividends indicates a consistent and potentially lucrative investment. Additionally, evaluating the trend of dividend increases provides insight into the company's financial strength and management's confidence in future earnings.
• Consistency in paying dividends is a reassuring sign, reflecting a company's reliability and commitment to shareholder value. For investors, dividends not only offer income but also contribute to the overall total return on investment.
• Companies with a history of regular and increasing dividends can attract income-focused investors seeking stable returns, making dividends a critical factor in building a well-rounded investment portfolio.
Interested in the overall sentiment for a particular period? Check out our news sentiment analysis tool.
Sentiment: Positive
Publish Date: 2025-01-09 15:38:00
NAARDEN, the Netherlands and MIAMI, Jan. 09, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS; “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that the Compensation Committee of NewAmsterdam's Board of Directors approved the grant of inducement share options covering an aggregate of 58,000 of NewAmsterdam's ordinary shares to two non-executive new hires and a grant of inducement share options covering 170,800 of NewAmsterdam's ordinary shares to Maryellen McQuade, the Company's new Chief People Officer. The share options were granted as an inducement material to the employees' acceptance of employment with NewAmsterdam pursuant to the NewAmsterdam Pharma Company N.V. 2024 Inducement Plan (the “2024 Inducement Plan”) and in accordance with Nasdaq Listing Rule 5635(c)(4).
Sentiment: Positive
Publish Date: 2024-12-13 17:16:00
NAARDEN, The Netherlands and MIAMI, Dec. 13, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS; “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced the closing of the previously announced underwritten public offering of (i) 14,667,347 of the Company's ordinary shares, nominal value €0.12 per share (the “Ordinary Shares”), at a public offering price of $24.50 per share, which includes the exercise in full of the underwriters' option to purchase an additional 2,550,000 Ordinary Shares, and (ii) to certain investors that so choose in lieu of Ordinary Shares, pre-funded warrants to purchase 4,882,653 Ordinary Shares at a public offering price of $24.4999 per pre-funded warrant, which represents the per share public offering price for the Ordinary Shares less the $0.0001 per share exercise price for each such pre-funded warrant (such offering, the “Offering”). All of the securities sold in the Offering were sold by the Company.
Sentiment: Positive
Publish Date: 2024-12-11 21:37:00
NAARDEN, the Netherlands and MIAMI, Dec. 11, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS; “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced the pricing of the previously announced underwritten public offering of (i) 12,117,347 of the Company's ordinary shares, nominal value €0.12 per share (the “Ordinary Shares”), at a public offering price of $24.50 per share and (ii) to certain investors that so choose in lieu of Ordinary Shares, pre-funded warrants to purchase 4,882,653 Ordinary Shares at a public offering price of $24.4999 per pre-funded warrant, which represents the per share public offering price for the Ordinary Shares less the $0.0001 per share exercise price for each such pre-funded warrant (“Pre-Funded Warrants,” such offering, the “Offering”). The proceeds to the Company from the Offering, before deducting underwriting discounts and commissions and offering expenses payable by the Company, are expected to be approximately $416.5 million. In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional 2,550,000 Ordinary Shares at the public offering price, less underwriting discounts and commissions. The Offering is expected to close on or about December 13, 2024, subject to satisfaction of customary closing conditions.
Sentiment: Positive
Publish Date: 2024-12-11 13:33:32
NewAmsterdam Pharma Company N.V.'s drug obicetrapib achieved positive results in phase 3 BROADWAY study, significantly reducing LDL-C in ASCVD and HeFH patients when added to statins. Positive data enables potential FDA regulatory application in 2025, with further data releases and peer-reviewed publications as upcoming catalysts. The seven major atherosclerotic cardiovascular disease markets is expected to reach $29.7 billion by 2034.
Sentiment: Positive
Publish Date: 2024-12-10 16:34:00
NAARDEN, The Netherlands and MIAMI, Dec. 10, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS; “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced the commencement of an underwritten public offering of $300.0 million of the Company's ordinary shares, nominal value €0.12 per share (the “Ordinary Shares”), and, to certain investors that so choose in lieu of Ordinary Shares, pre-funded warrants to purchase Ordinary Shares (“Pre-Funded Warrants,” and such offering, the “Offering”). All Ordinary Shares and Pre-Funded Warrants to be sold in the proposed Offering will be sold by the Company. In addition, the Company expects to grant the underwriters a 30-day option to purchase up to an additional $45.0 million of Ordinary Shares, less underwriting discounts and commissions. The proposed Offering is subject to market and other conditions and there can be no assurance as to whether or when the proposed Offering may be completed, or as to the actual size or terms of the proposed Offering.
Sentiment: Neutral
Publish Date: 2024-12-10 11:14:25
On Tuesday, NewAmsterdam Pharma Company N.V. NAMS revealed topline data from its Phase 3 BROADWAY clinical trial evaluating obicetrapib in adult patients with atherosclerotic cardiovascular disease (ASCVD) and/or heterozygous familial hypercholesterolemia (HeFH), whose LDL-C is not adequately controlled, despite being on maximally tolerated lipid-lowering therapy.
Sentiment: Positive
Publish Date: 2024-12-10 07:00:00
-- Achieved primary endpoint of LS mean reduction vs placebo in LDL-C on top of maximally tolerated lipid modifying therapies at day 84 with statistically significant reduction (p
Sentiment: Positive
Publish Date: 2024-12-06 16:01:00
NAARDEN, The Netherlands and MIAMI, Dec. 06, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that the Compensation Committee of NewAmsterdam's Board of Directors approved the grant of inducement share options covering an aggregate of 79,000 of NewAmsterdam's ordinary shares to two non-executive new hires. The share options were granted as an inducement material to the employees'acceptance of employment with NewAmsterdam pursuant to the NewAmsterdam Pharma Company N.V. 2024 Inducement Plan (the “2024 Inducement Plan”) and in accordance with Nasdaq Listing Rule 5635(c)(4).
Sentiment: Negative
Publish Date: 2024-11-20 10:10:45
NewAmsterdam Pharma crashed Wednesday after the company said its experimental cholesterol treatment lowered "bad" LDL by roughly 50% The post NewAmsterdam Dives — And Sacrifices A Cup Base — Despite A Winning Cholesterol Study appeared first on Investor's Business Daily.
Sentiment: Negative
Publish Date: 2024-11-18 15:20:00
– Met primary endpoint with LDL-C mean reduction versus placebo of 36.3% at day 84 and 41.5% at day 365 – – Lp(a) mean reduction versus placebo of 45.9% at day 84 and 54.3% at day 365 – – Total LDL-P mean reduction versus placebo of 52.5% at day 180, with small LDL-P reduction of 102.4% – – Safety results comparable to placebo – NAARDEN, the Netherlands and MIAMI, Nov. 18, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced additional results from the Company's Phase 3 BROOKLYN clinical trial (NCT05425745) evaluating obicetrapib in adult patients with heterozygous familial hypercholesterolemia (“HeFH”), whose LDL-C is not adequately controlled, despite being on maximally tolerated lipid-lowering therapy.
Sentiment: Positive
Publish Date: 2024-11-01 17:26:00
NAARDEN, The Netherlands and MIAMI, Nov. 01, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that the Compensation Committee of NewAmsterdam's Board of Directors approved the grant of inducement share options covering an aggregate of 97,600 of NewAmsterdam's ordinary shares to two non-executive new hires. The share options were granted as an inducement material to the employees' acceptance of employment with NewAmsterdam pursuant to the NewAmsterdam Pharma Company N.V. 2024 Inducement Plan (the “2024 Inducement Plan”) and in accordance with Nasdaq Listing Rule 5635(c)(4).
Sentiment: Negative
Publish Date: 2024-10-28 16:30:00
NAARDEN, The Netherlands and MIAMI, Oct. 28, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that it will present additional safety and efficacy data from the pivotal Phase 3 BROOKLYN study evaluating obicetrapib in patients with Heterozygous Familial Hypercholesterolemia in a late-breaking oral presentation at the 2024 American Heart Association (AHA) Scientific Sessions, taking place November 16 – 18, 2024 in Chicago, Illinois. Additionally, NewAmsterdam announced that company management will participate in the Jefferies London Healthcare Conference, taking place November 19 – 21, 2024 in London. Details are as follows:
* The sentiment analysis presented is generated through an algorithm and may be subject to inaccuracies. Users are advised to corroborate key information and employ further analytical methods prior to making critical decisions.
Get instant AI-powered professional insights:
💡Generate AI Technical Analysis ReportUnderstand the chart below:
Interpret Technical Indicators
| Indicator | Bullish | Bearish |
|---|---|---|
| Price and EMA ⓘ | Price crosses above EMA | Price crosses below EMA |
| Short-Term vs Long-Term EMA ⓘ | Short EMA crosses above Long EMA | Short EMA crosses below Long EMA |
| Volume ⓘ | Increasing volume during price uptrend | Increasing volume during price downtrend |
| MACD ⓘ | MACD crosses above Signal Line | MACD crosses below Signal Line |
| RSI ⓘ | RSI is below 30 (oversold) and starts to rise above 30 | RSI is above 70 (overbought) and starts to decline below 70 |
| Candlestick Patterns ⓘ | Bullish candlestick patterns | Bearish candlestick patterns |
Copyright © 2024 Sirius Investors
All rights reserved
